Manufacturing, Gene Therapies

MilliporeSigma Launches Excipient Platform for Protein-Based Therapies

October 06, 2021

New excipients for protein-based drug products reduce viscosity while maintaining protein stability.

Celularity and Oncternal Therapeutics to Research Placental-Derived Cellular Therapies

September 22, 2021

Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.

Novartis Acquires Arctos Medical, Expanding Optogenetics Profile

September 22, 2021

Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

September 14, 2021

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

Aptamer Group, Bio-Works Technologies Collaborate on Affinity Resin for Gene Therapy Manufacturing

August 26, 2021

Aptamer Group and Bio-Works Technologies are partnering up to develop a new affinity resin for improved purification and scale-up of gene therapy vectors.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

August 19, 2021

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

August 09, 2021

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

University of Sheffield and CGT Catapult Launch Innovative Gene Therapy Program

August 04, 2021

The University of Sheffield has launched an innovative gene therapy program that could pave the way for novel treatments for neurodegenerative diseases.

PerkinElmer to Acquire BioLegend in $5.25-Billion Deal

July 27, 2021

PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion.

Pall Enters Multi-Million Dollar Contract with Exothera for Viral Vector Manufacturing

July 21, 2021

Pall has secured a manufacturing contract with Exothera for the suspension-based manufacture of gene therapies and viral vector-based vaccines.